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Purpose of the Study - The study aim was to develop a measure of self-reported QoL 
for people with mild to moderate dementia based on their views - the Bath 
Assessment of Subjective Quality of Life in Dementia (BASQID). 
Design and Methods - The measure was developed through multiple stages. Two 
field tests of the measure (n=60 & n=150) enrolled people with dementia from a 
memory clinic and the data were used to analyse the psychometric properties of the 
scale. Nested within this was a longitudinal investigation of 36 Alzheimer’s disease 
patients prescribed with acetylcholinesterase inhibitors. 
Results - The BASQID contains 14 items assessing a range of QoL issues.  Results 
show that the BASQID satisfies the criteria of a valid, reliable, and acceptable 
assessment of subjective QoL. Scores were responsive to changes in QoL, over 3-
months. Low association between the BASQID and Mini Mental State Examination 
indicates that cognitive function may influence QoL, but is an indirect measure of the 
QoL experienced during dementia. 
Implications – The BASQID provides a means of better understanding the 
experiences, perceptions, and beliefs of people with dementia. It does this through 
acknowledgement of the many influences on QoL, over and above health status. The 
BASQID can be used alongside objective assessments of dementia to provide a 
complete appraisal of a person’s QoL. 
 
Key words: Psychometrics, Self-report, Alzheimer’s disease, Outcome assessment, 
Well-being  
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Introduction 
 
With no cure available, one of the main goals for pharmacological, behavioural, social 
and environmental interventions in dementia must be the maintenance or 
improvement of the patient’s quality of life (QoL). Quality of life is a 
multidimensional construct that should include not only objective (observable) 
indices of well-being judged against socio-normative criteria, but also the individual’s 
own subjective perception of their position in life (Lawton, 1991). Global concerns of 
patients in relation to their own values and expectations must be considered if an 
acceptable standard of care is to be provided for people with dementia. With the 
increasing trend towards patients presenting at earlier stages of the disease, and being 
involved in decisions about their care and treatment, it is important that clinicians 
have accurate information about the overall impact on well-being of both the disease, 
and any potential intervention (Schneider, 2001).  
 
Measuring Quality of Life in Dementia 
In dementia, there has been a long unchallenged assumption in research and practice 
that people with dementia are unable to give a reliable account of their own QoL 
(Cotrell & Schulz, 1993). Measurement has therefore focused on observable aspects 
of QoL, such as symptom severity and function, with only fleeting reference to the 
person’s subjective perceptions (Stewart, Sherbourne & Brod, 1996). Consequently, 
many QoL measures risk being little more than health status assessments that 
replicate much of the information that can be obtained from many other disability and 
disease burden measures (Gill & Feinstein, 1994; Leplege & Hunt, 1997). There is 
also the danger that by conceptualising QoL for those with dementia in terms of 
negative constructs such as loss and disability, QoL research will focus on minimising 
negative outcomes, to the exclusion of maximising the potential for positive life 
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experiences. 
 
The medical model of QoL places most emphasis on functional capacity, stressing the 
ability to perform everyday tasks and fulfil premorbid social and occupational roles 
(Leplege & Hunt, 1997). Implicit within the medical model is the notion that there is 
an optimum level of functioning, to which all people should aspire, whereby those 
who are impaired or disabled have, by definition, a poorer QoL. This leads to the 
questionable assumption that positive QoL cannot be achieved in the presence of 
physical deficits. Similarly, whilst health is undoubtedly an important component of 
QoL, the two terms should remain distinct (Hunt, 1997), as evidence suggests that it 
is possible for people in poor health to report a good QoL (Albrecht & Devleiger, 
1999). In developing QoL measures, care must be taken to differentiate between 
causal variables (e.g. symptoms and reduced function) that affect QoL, and outcome 
variables that reflect QoL (Fayers & Machin, 2000). By weighting QoL assessments 
heavily towards the presence or absence of symptoms like memory loss and disability, 
the possibility is excluded that some people may be able to adapt or adjust to their 
health problems, so maintaining or even improving their QoL (Ettema, Droes, de 
Lange, Mellenbergh & Ribbe, 2005). Indeed, evidence indicates that there is little or 
no association between QoL and severity of cognitive impairment for people with 
mild to moderate-stage dementia (Hoe, Katona, Roch & Livingston, 2005; Logsdon, 
Gibbons, McCurry & Teri, 1999; Ready, Ott, Grace & Fernandez, 2002; Thorgrimson 
et al., 2003). Just because an individual’s cognition worsens, we cannot assume that 
this inevitably leads to a worsening of QoL. 
 
It has been argued that QoL can only be adequately measured by determining the 
opinions of patients, rather than relying on the views of ‘experts’ e.g. clinicians, or 
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carers (Gill & Feinstein, 1994) which may be reliable for observable aspects of 
behaviour and ability, but are unsuitable for inferring subjective experience and 
feelings (Berkowitz, Du, Kazis & Lewis, 1995). Recent research suggests that with 
careful attention to the wording, structure and format of questions, self-reported QoL 
is possible using standardised measures (Brod, Stewart, Sands & Walton., 1999; 
Logsden, Gibbons, McCurry & Teri, 2002). Moreover, it provides consistent and 
reliable information regarding QoL issues (Feinburg & Whitlatch, 2001; Mozley et al, 
1999).  
 
Reviews of QoL measures that could be used in dementia highlight a variety of 
suitable tools (Ettema et al., 2005; Ready & Ott, 2003) but few have been developed 
specifically for dementia, and even fewer are designed to gather information directly 
from the person with the condition. The Dementia Quality of Life Instrument (DQoL) 
(Brod et al., 1999) is a measure designed solely for patient-administration; it assesses 
a person’s ‘sense of well-being’ and ‘aesthetics’. Common indicators of QoL such as 
social interaction, mobility and activity performance were excluded with the aim of 
minimising respondent burden and because these domains are seen as more suited to 
objective assessment. The DQOL therefore focuses primarily on feeling states and 
mood. However Jennings (1999) suggested that QoL judgements based on feelings 
such as happiness are too simplistic; it is not plausible to say that a person’s QoL is 
good just because pleasurable sensations outnumber the unpleasant ones. An 
evaluation of life areas such as satisfaction is central to the concept and assessment of 
QoL (Lawton, 1997). The QoL-AD (Logsdon et al., 1999) is a brief measure designed 
for both patient and proxy completion, with respondents asked to rate general life 
areas such as physical health, energy, mood, living situation, memory, family, 
marriage, friends, chores, fun, money, self and life as a whole on a scale from poor to 
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excellent. However one might argue that this approach differs from an evaluation of 
satisfaction in that it does not allow for the possibility that the person may rate his/her 
performance in a particular life domain as poor but report higher levels of satisfaction 
due to a low perceived importance of that domain, or the successful use of coping and 
adaptation. 
 
There is therefore a need to develop a new measure of QoL for use by people with 
mild to moderate-stage dementia, to subjectively assess a range of QoL domains 
particularly relevant to this population; including positive and negative feeling states, 
and with judgement or evaluation of various life areas. The measure should avoid 
inclusion of causal variables such as symptom severity that do not necessarily reflect 
QoL status per se, and should promote the assessment of positive constructs, such as 
feelings of self-worth and life satisfaction.  
 
Development of the Bath Assessment of Subjective Quality of Life in Dementia 
(BASQID) 
The BASQID was developed from the perspective of the person with dementia and 
this philosophy remained central to each stage of development. These stages had 
previously included the qualitative development of a conceptual framework, 
generated from in-depth interviews, with thirty people with mild to moderate-stage 
dementia, exploring in their own language and ideas, those issues that were relevant 
and important to their QoL, and the ways in which dementia impacted on these areas. 
Further, structured interviews with people with dementia examined understanding, 
and the relative importance, of the emergent QoL domains, and provided an 
opportunity to explore the potential format of questions, and response choices. 
Results indicated that presenting questions and response scales both visually and 
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orally may be beneficial in helping the respondent attend to questions, and respond to 
choices. An initial pool of 44 items was produced, based on the domain and facet 
structure from the conceptual framework.  
 
The conceptual framework and details of item reduction are presented elsewhere 
(Trigg, Jones & Skevington, 2007). This paper reports on the psychometric properties 
of the final BASQID measure, including the relationship of BASQID scores to other 
clinical indicators, such as cognition. 
 
Method 
 
Design 
The field-testing of the BASQID item pool was split into two stages, so that the initial 
pool of items could be reduced before large numbers of people were assessed on the 
measure within a memory clinic setting.  The main purpose of the first field test 
(Stage 1) was to carry out item reduction analyses along standard psychometric 
procedures, and applying criteria provided by the Scientific Advisory Committee of 
the Medical Outcomes Trust (2002).  At Stage 1, the 44-item version of the BASQID 
was administered with the15-item Geriatric Depression Scale (GDS-15) (Sheikh & 
Yesavage, 1986). The WHOQOL-BREF (The WHOQOL Group, 1998a) was also 
completed by the spouse/caregiver and not the patient, as the burden on participants 
was of primary concern at this stage of development. It was felt that the addition of a 
further assessment such as the WHOQOL on top of the 44-item BASQID and GDS 
would be excessive.   
 
A second field test (Stage 2) followed, when a shortened version of the BASQID (21 
items) was administered, with the Mini Mental State Examination (MMSE) (Folstein, 
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Folstein & McHugh, 1975). This information was used to produce the final BASQID 
instrument, and explore the contended relationship between QoL and cognition.   
 
Nested within the Stage 2 sample was a modest longitudinal study of 36 participants 
who were beginning treatment on one of the three available acetylcholinesterase 
inhibitors for mild-moderate Alzheimer’s disease (AD) (Sample 2a). They were tested 
twice, at 3-month intervals, to provide information on validity and responsiveness of 
the BASQID scores to changes in clinical condition.  
 
Participants 
Sixty people with dementia (Sample 1) were included in the Stage 1 field test as 60 
was calculated as being sufficient to detect significant correlations (>0.3) between 
questionnaire items, and between measures for the purpose of construct validity 
testing. Thirty of these were re-assessed two weeks later, and the scores used to 
examine test-retest reliability, as 30 would allow the detection of significant 
correlations (>0.7) between the two administrations of the measure, albeit with large 
standard errors. For Sample 2, 150 patients were recruited, as this was sufficient to 
allow detailed analysis of the structure and scaling properties of the BASQID using 
factor analytic techniques. MacCallum, Widman, Zhang & Hong (1999) indicate that 
between 100-200 cases is adequate when there are few factors, and variables have 
communalities (common variance) of  > 0.5. Nested within Sample 2 was a subgroup 
of 36 participants who were beginning treatment on one of the three available 
acetylcholinesterase inhibitors for mild-moderate AD. They were assessed on the first 
occasion that these drugs were prescribed, and then again, three months later. 
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Participants were consecutive admissions to a memory clinic during a 15-month 
period, who satisfied the inclusion criteria of a positive diagnosis of dementia, 
according to DSM-IV (American Psychiatric Association, 1994), and a MMSE score 
of 12 or above, signifying a mild to moderate stage (National Institute of Clinical 
Excellence, 2001). Previous research shows this to be the level at which patients are 
able to directly report on QoL issues (Logsdon et al., 1999; Mozley et al., 1999). 
Exceptionally, some patients with scores below 12 were recruited if the clinical staff 
judged that they might be able to complete the assessment, and if their low MMSE 
score was due to poor sight or hearing.  Participants were excluded if they had already 
participated in the BASQID development, or did not have English as their first 
language. At Stage 1, the participation of a spouse or caregiver of the person (where 
available) was requested to complete proxy assessments on behalf of the patient for 
validation purposes. 
 
Materials 
Bath Assessment of Subjective QoL in Dementia (BASQID) 
The number of items contained within the measure was different for the two field 
tests: 44 items for Stage 1, into which the 21 items tested at Stage 2 were embedded. 
The items were administered via interview, with the interviewer presenting each 
question visually and orally to the person with dementia.  Each item is printed on an 
individual card in large sans serif font. Response scales are printed on individual 
cards (same font size) and are set out horizontally, with vertical lines separating the 
five scalar points. Two response scales are used within the BASQID; ‘not at all 
satisfied, a little satisfied, satisfied, very satisfied, extremely satisfied’ and ‘not at all, 
a little, a moderate amount, quite a lot, a great deal’. Only words define each point on 
the scale, not the scores associated with each response. All items are scored 0-4, so 
 11
that low scores indicate poor QoL.  
 
Geriatric Depression Scale (15-item version) 
The 15-item GDS (Sheikh & Yesavage, 1986) demonstrates acceptable reliability as a 
screening instrument (alpha = 0.81) for depression. It has advantages over shorter 
versions in that the total score can be used as a measure of the severity of the 
depressive episode (Almeida & Almeida, 1999). 
 
WHOQOL-BREF 
 
The WHOQOL-BREF is a 26-item short form version of the WHOQOL-100 
(WHOQOL Group, 1998b).  It is a generic assessment of QoL across four domains: 
Physical health, Psychological, Social relationships, and Environment (Skevington, 
Lofty & O’Connell, 2004). Internal consistency reliability has been demonstrated by 
Cronbach’s alpha values of between 0.66-0.88 for the four domains, in an 
international sample of well and sick people. The WHOQOL-BREF was found to be 
comparable to the WHOQOL-100 in terms of discriminating between the QoL of ill 
and well respondents.  
 
Mini Mental State Examination 
 
The MMSE (Folstein et al., 1975) is a widely used measure of cognitive function. The 
MMSE has a maximum score of 30 points. It assesses aspects of orientation to time 
and place, registration, attention, calculation, recall, language and visual construction. 
The MMSE scores validly discriminate between people with dementia, depression, or 
cognitive impairment with depression (Folstein et al., 1975). Test-retest reliability 
was measured at 0.89, with inter-rater reliability at 0.83. Validation of the measure is 
reported (Tombaugh & McIntryre, 1992) however it must also be noted that the 
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MMSE has been criticised for its dependency on education and age (Tombaugh & 
McIntryre, 1992) and on race, ethnicity and language (Ramirez et al., 2006). 
 
Clinician Global Change Rating (CGCR) Forms 
A Clinician Global Change Rating (CGCR) of QoL was completed for each 
participant in Sample 2a as part of the assessment of responsiveness. Responsiveness 
testing requires the comparison of measure changes to an accepted indication of 
change as the external standard (Husted, Cook, Farewell & Gladman, 2000). However 
for QoL measurement, no such gold-standard measure exists. Terwee, Dekker, 
Wiersinga, Prummel & Bossuyt (2003) suggest that in such cases, global ratings of 
change by clinicians might be appropriate. While admittedly an imperfect measure, 
because a physician saw all participants, this was seen as the most appropriate form of 
proxy QoL rating in the current study. The CGCR consisted of a transitional question 
in which the physician used a 5-point scale to rate whether the participant’s QoL was: 
a lot worse, a little worse, the same, a little better or a lot better, compared to three 
months previously.  
 
Procedure 
At Stage 1, interviews were conducted in the participants’ home or at the memory 
clinic, depending on the preference of patient and carer. Informed consent was 
obtained from both parties. The carer completed the WHOQOL-BREF on behalf of 
the patient. The BASQID and then the GDS-15 were administered via interview to the 
patient. Thirty respondents were revisited two weeks after the initial administration 
when patients completed the BASQID alone, to provide data for calculation of test-
retest reliability statistics. 
 
All assessments at Stage 2 were conducted in the memory clinic as part of the 
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patients’ scheduled visit. Routine cognitive assessments and evaluations completed by 
memory clinic staff included administration of the MMSE. The researcher was then 
introduced to the patient and explained the purpose of the QoL assessment. Informed 
consent was obtained from the participant, and the BASQID administered.  
 
For participants in Sample 2a, the procedure above was completed twice. The first 
assessment was administered prior to the participant being prescribed an 
acetylcholinesterase inhibitor for the treatment of AD. The second assessment was at 
their three-month follow-up appointment where the effectiveness of the drug was 
evaluated by the physician supervising the prescription of the intervention, using the 
CGCR form. 
 
Statistical Analysis 
Data from Stage 1 was revisited once the final BASQID scales had been produced, as 
part of construct validity and test-retest reliability analysis. The relationship between 
BASQID scores, the GDS and the four subscales of the WHOQOL-BREF was 
examined using Pearson correlation coefficients. Intraclass correlation coefficients 
were used to explore the temporal stability of the BASQID. 
 
Data from Stage 2 was used to develop the final BASQID instrument retaining only 
the items and subscales that demonstrated sound psychometric properties. The 
dimensionality of BASQID items was explored using Principal Components Analysis 
(PCA) with a Varimax, orthogonal rotation. In an iterative process, factors were 
retained if eigenvalues exceed 1.0. Items that failed to load at least 0.4 on any factor 
or that cross-loaded on more than one factor (at above 0.4) were considered for 
possible rejection from the measure. Once items had been eliminated, the best-fit 
model was re-run. It is noted that these analyses are exploratory, and that other 
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models, e.g. a bifactor (Gibbons et al., 2007) or a random intercept model (Maydeu-
Olivares & Coffman, 2006) should be examined in future analyses. The latter model 
is appropriate when item wording may affect item response, and the bifactor model is 
informative with respect to the presence of a general factor in addition to two 
subfactors that capture residual covariation. 
 
Internal consistency of the resultant scales were examined using Cronbach’s 
coefficient alpha. Secondary analysis was conducted to investigate the effect of 
participant cognitive status on internal consistency. Sample 2 was divided into tertiles 
according to MMSE scores (<16, 16-20, >20) and Cronbach’s alpha recalculated for 
the BASQID scales within each tertile (Logsdon et al., 2002).  
 
Responsiveness of the scales was assessed through calculation of effect size statistics 
(change score for the instrument divided by the standard deviation of the baseline 
scores; Kazis, Anderson & Meenan, 1989). These effect sizes were compared to the 
CGCR to assess whether the BASQID was able to detect clinically important 
observed changes in patients’ QoL. Spearman’s correlations examined agreement 
between the effect sizes recorded on the BASQID, and changes in QoL as rated on the 
CGCR form. Secondary analysis involved splitting the sample into three groups 
according to clinician judgements about improved QoL, a worse QoL or the same 
QoL, compared to three months ago, and comparing effect sizes across the groups. 
 
The construct validity of the BASQID was explored thorough examination of 
Pearson’s correlations between BASQID scores and participant cognitive status, age, 
GDS-15 and the carers’ proxy judgement using the WHOQOL-BREF. An 
independent samples t-test explored differences in BASQID scores for males and 
 15
females. It was hypothesised that BASQID scores would show low-moderate 
significant correlations with proxy ratings of QoL on the WHOQOL-BREF. As there 
is a strong relationship between self-reported QoL and mood (Logsdon et al., 2002; 
Thorgrimson et al., 2003), McDowell and Newell (1996) suggest that the correlation 
between QoL and depression may be as high as 0.6, so a moderate correlation was 
expected between BASQID scales and GDS-15. In line with results from other self-
report QoL instruments, significant correlations were not expected between BASQID 
scales and participant MMSE scores (Logsdon et al., 1999; Ready et al., 2002; 
Thorgrimson et al., 2003), or between BASQID scores and participant age or sex. 
One-way analysis of variance was used to explore differences in BASQID score 
across age and MMSE tertiles. 
 
Results 
 
The properties of the BASQID outlined below are based on data from Stages 1 and 2, 
but data from these two stages was analysed separately. Table 1 displays the 
characteristics of the samples used. In Sample 2, 11 participants had MMSE scores of 
less than 12.  
 
In Stage 1, seven participants were unable to complete all 44 items. Of these, five 
provided answers for at least 42 of the items. In Stage 2, seven people out of 150 were 
unable to complete the 21-item measure. All except one had MMSE scores of 12 or 
below. Reasons for non-completion of items included fatigue, confusion, poor 
attention, and poor language skills.  
 
The item reduction procedure is published elsewhere (Trigg et al., 2007) and the 
analysis in this paper is conducted on the 14 extracted items that were found to be the 
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‘best’ items out of 44 in psychometric terms, and form the final measure. 
   
Insert Table 1 here 
 
BASQID Scales 
The BASQID measure contains 14 items.  In Stage 1, the level of missing data for 
these items was minimal, with any one question having no more than three missing 
values (5%).  For Stage 2 the level of missing data within the 14 items was no more 
than 4.66% (7/150). Listwise deletion of cases was employed where there was 
missing data in the variables used for analyses.  
 
A total score for the 14-item scale (BASQID), from 0-100, is derived by multiplying 
the sum score by 100/(m x (k-1)) where m represents the number of items in the scale 
and k represents the number of response choices. The distribution of scores on the 
BASQID had a mean of 61.47 (SD = 14.25, range = 23.21–89.29). 
 
Insert Figure 1 here 
 
A PCA was used to explore the dimensionality of the 14 items, using data (n=143) 
from Stage 2. The Kaiser-Meyer-Olkin statistic had a value of .90, indicating an 
excellent level of sampling adequacy. Bartlett’s test of sphericity was significant, 
indicating that PCA was appropriate. Both the Kaiser criterion, of retaining factors 
with an eigenvalue of greater than one, and the scree test (see Figure 1) suggest that 
the items within the BASQID may be organised according to two orthogonal 
dimensions. Although the test of scree suggests an essentially unidimensional result (a 
ratio of 4 to 1 of the first to the second eigenvalue, with the second only slightly over 
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1), the presence of two components cannot be ruled out without further confirmatory 
analyses with a cross-validation sample and other models. The content of the items 
within each dimension suggest that Component 1 (eigenvalue = 5.90) represents a 
Life Satisfaction (LS) subscale and Component 2 (eigenvalue = 1.36) represents a 
Feelings of Positive QoL (FPQ) subscale. The content of these items and loadings on 
the two components are displayed in Table 2.  
 
Insert Table 2 here 
 
Subscale scores were calculated in the same manner as those for the BASQID. The 
distribution of scores for the two subscales (n=143) were distributed around a mean of 
58.69 for LS (SD = 14.92, range = 6.25–90.63) and 65.18 for the FPQ (SD = 16.85, 
range = 0–95.83).  
 
Reliability 
Internal Consistency 
The internal consistency of the BASQID was calculated using data from Stage 2. 
Cronbach’s alpha for the BASQID was 0.89, whilst alphas for LS and FPQ subscales 
were 0.84 and 0.83 respectively (n=143), indicating acceptably high internal 
consistency. When Sample 2 was divided into tertiles on the basis of MMSE scores, 
internal consistency was acceptable for each of the three groups, with the lowest at 
0.78 for the LS scale in the MMSE<16 group (n=47). 
 
Reproducibility 
Using Sample 1 data, test-retest reliability for the BASQID (n=29) demonstrated a 
non-significant difference between the two administrations (Time 1 – Time 2) of 0.65 
(s.d. = 3.89, t = -0.85, p > 0.05) with an intraclass correlation coefficient of 0.85 (95% 
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CI = 0.70–0.93). For the LS subscale there was a non-significant difference in mean 
scores between the two administrations of -2.58 (s.d. = 8.43, t = 1.65, p > 0.05) with 
an intraclass correlation coefficient of 0.79 (95% CI = 0.59-0.89). Difference in mean 
scores for the FPQ subscale was -0.30 (s.d. =  8.48, t = 0.18, p > 0.05) with an 
intraclass correlation coefficient of 0.85 (95% CI = 0.70–0.93). 
 
Validity 
Content Validity 
The content of the BASQID is based on a framework derived from qualitative work, 
that conceptualised subjective QoL as the person’s evaluation of multiple QoL 
domains of health, function, leisure, sleep, energy, mobility, environment, mood, and 
social interaction, as well as feelings of need fulfilment, identity and affect, and all 
components of this framework were included as items in the initial pool (Trigg et al, 
2007). The 14 items in the BASQID relate to the QoL domains; health, social 
interaction, function, mobility, being occupied, energy and psychological well-being. 
 
Construct Validity 
As expected, scores on the BASQID show moderate correlation with the GDS-15, and 
low to moderate association with the proxy-completed WHOQOL-BREF (Table 3). 
The social subscale of the WHOQOL-BREF, and the GDS-15 displayed the highest 
level of association with BASQID scales.  
 
Insert Table 3 here 
 
Discriminant validity was supported as the BASQID failed to display significant 
correlations (n=143) with either participant age, or scores on the MMSE. This lack of 
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association was confirmed by splitting the sample into MMSE tertiles (<16, 16-20, 
>20) and comparing scores on the BASQID across the groups. No significant 
differences in scores were found for the BASQID (F(2, 140) = 0.41, p > 0.05), for LS 
subscale ( F(2, 140) = 0.12, p > 0.05) or FPQ subscale ( F(2, 140) = 0.75, p > 0.05). 
Similarly the sample was split into age tertiles (<77, 77-81, >81) and BASQID scores 
compared across the three groups. No significant differences were found for the 
BASQID (F(2, 140) = 0.58, p > 0.05), for LS ( F(2, 140) = 0.26, p > 0.05) or FPQ ( 
F(2, 140) = 0.86, p > 0.05). An independent t-test explored differences between 
BASQID scores for men (n=58) and women (n=85) in Sample 2, and found no 
significant difference for the BASQID (t = 0.19. p >0.05), LS (t = -0.26, p > 0.05) or 
FPQ (t = 0.70, p > 0.05). 
 
Responsiveness 
Ten of the 36 people in Sample 2a, were judged by clinicians to have an improved 
QoL after three months, 23 remained the same, and three deteriorated. Effect size 
statistics were calculated for the BASQID and the two subscales (see Table 4), and 
significant correlations found between clinician global ratings of QoL change effect 
size statistics (for BASQID, r = .50, p < 0.01; for LS, r = 0.49, p < 0.01; for FPQ, r = 
0.33, p < 0.05).  
 
Insert Table 4 here 
 
Participants were grouped according to the CGCRs of QoL so that effect sizes for 
those who had better, same or worse QoL could be compared (Table 5) and there is a 
trend in the data. Small/medium negative effect sizes were found on the BASQID, LS 
and FPQ for the three people deemed to have a worse QoL; negligible effect sizes for 
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the 23 people who remained stable; and small/medium positive effect sizes for the 10 
people considered to have improved QoL. Small samples in two groups meant that 
these differences did not reach statistical significance and confidence intervals were 
wide.  
 
Discussion 
 
The primary aim of this research was to develop a measure of QoL that was 
appropriate for self-report by people with dementia. Examination of the properties of 
the BASQID suggests that this has been achieved. The BASQID is brief and easy to 
administer and is well received by respondents, with positive wording used 
throughout items. The visual presentation of questions and responses is an important 
factor in minimising the burden of response. A parsimonious approach was taken with 
regard to the inclusion of items within the BASQID. The BASQID is a disease-
specific measure for people with mild to moderate dementia, insomuch as it focuses 
on domains of QoL particularly relevant for this population. The fact that only a 
relatively narrow subset of items has been chosen for inclusion within the measure 
does have implications for how scores are interpreted. It would be wrong to suggest 
that the BASQID provides a comprehensive profile of QoL, as domains that were part 
of the initial conceptual framework, such as the adequacy of the person’s environment 
and sleep, are not included.  Rather, it assesses a subset of QoL items that appear to 
be useful in discriminating between individuals with dementia and exploring changes 
in QoL over time in response to disease change or intervention. If a comprehensive 
assessment of QoL is required, then further research should address the question as to 
whether existing generic profiles of QoL are appropriate for this population. 
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The internal consistency of the 14-items indicates that the BASQID may be used as a 
single scale of QoL. However preliminary results from the PCA suggests that the 14 
BASQID items may contain two independent subscales; LS and FPQ. It must be 
acknowledged that the separation of items into a satisfaction component alongside a 
component relating to feelings and mood may be an artefact induced by the item 
stems, as spurious factors can be induced by wording, e.g., positively and negatively 
worded and ordering of items (see Marsh, 1996). However this separation of 
constructs is supported by existing conceptualisations of QoL (Brod et al., 1999; 
Ferrans & Powers, 1992; Jennings, 1999; Lawton, 1997) and may allow a more 
detailed investigation of QoL in people with dementia. Further evaluation of the 
dimensionality of the BASQID using confirmatory analyses is warranted, with larger 
samples and other models, to confirm the independence of these subscales.  
 
Overall, the BASQID displays strong psychometric properties is brief and acceptable 
to patients. The BASQID displays high internal consistency and acceptable test-retest 
reliability, in line with other measures such as the QoL-AD and DQoL. As with the 
DQoL and QoL-AD, the BASQID does not show any association with MMSE scores, 
but does display a strong association with depression. Construct validity was 
supported through significant correlations with proxy ratings of QoL. Although 
significant, these correlations were low to moderate in size, which concurs with the 
literature (Novella et al., 2001). As with any new measure, ongoing validation with 
large samples is needed in order to determine the usefulness of the measure in 
different settings with different groups of individuals. The samples used in the 
development of the BASQID were recruited from a memory clinic and therefore will 
have included people more likely to be receiving support and intervention from health 
and social services and accustomed to undergoing formal assessment. The participants 
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were English-speaking, mainly Caucasian, individuals and therefore there is the 
possibility that QoL issues important to other ethnic groups are not represented. 
 
Although sensitive to the effects of dementia, it would seem that the BASQID is not 
simply reflecting the effects of worsening symptoms or changes in disease. Whilst 
changes in cognition and function may influence QoL, they should not be taken as a 
direct measure of QoL. There is a low level of association between the BASQID and 
the physical domain on the WHOQOL-BREF, but perhaps more significantly there is 
a lack of association between the BASQID and MMSE scores. This concurs with 
current research evidence (Hoe et al., 2005; Logsdon et al., 1999; Ready et al., 2002; 
Thorgrimson et al., 2003) and adds weight to the argument that cognitive ability is not 
necessarily a predictor of subjective QoL. Indeed, the work of Kitwood (1995) has 
demonstrated that it is possible that the person with dementia can experience positive 
long-term changes. 
 
The responsiveness of BASQID scores to changes in QoL over a three-month period 
experienced by people receiving an acetylcholinesterase inhibitor for the treatment of 
AD was explored. Effect sizes for the BASQID showed significant associations with 
the QoL change ratings of clinicians. Data from this study is strongly indicative that 
the BASQID is responsive to changes in QoL, but is somewhat limited due to the 
relatively small sample size employed in this study and the use of physician ratings of 
QoL as the external standard of QOL change. Further work on responsiveness is 
needed, with longer follow up periods to chart changes in QoL brought about through 
changes in other variables, such as lifestyle, living arrangements, care provision and 
non-pharmacological therapeutic interventions. Studies such as this should combine 
quantitative and qualitative methodologies in order to assess how changes in 
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BASQID scores relate to accounts of significant life events reported by patients and 
carers.  
 
As a self-report measure, the BASQID should complement existing objective 
measures of health, disability and QoL, giving a more complete appraisal of the QoL 
of people with dementia. The BASQID has been developed to provide a means of 
better understanding the experiences, perceptions, and beliefs of people with 
dementia. It does this through acknowledgement of the many influences on QoL, over 
and above health status. By adopting a biopsychosocial framework, the BASQID 
allows people to report QoL levels that might differ from that suggested by objective 
indices of health and disability. This subjective viewpoint on issues of life satisfaction 
and feelings of positive QoL may provide caregivers and researchers an important 
insight into treatments and therapies that have personal benefits for the person with 
dementia. With the availability of measures such as the BASQID, there is no longer a 
reason to ignore the perspective of the person with dementia when evaluating 
approaches to dementia care. 
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Table 1 
Sample characteristics from BASQID field tests 
  Sample 1 Sample 2 
   
(n=60) 
Whole sample 
(n=150) 
Sub-sample 2a 
(n=36) 
Probable  Alzheimer’s / Mixed  49 (82%) 123 (82%) 36 
diagnosis Vascular 8 (13%) 19 (13%)  
 Frontotemporal 3 (5%) 8 (5%)  
     
Cognitive MMSE mean (s.d.)  18.44 (4.07) 18.06 (4.63) 18.38 (3.83) 
ability MMSE median (range) 18 (12-26) 18 (5-28) 18 (11-26) 
     
Living  Living alone 8 (13%) 25 (17%) 4 (11%) 
arrangement Living with spouse 45 (75%) 93 (62%) 25 (69%) 
 Living with 
relative/other 
5 (8%) 21 (14%) 4 (11%) 
 Residential 
accommodation 
2 (3%) 11 (7%) 3 (8%) 
     
Sex Male 28 (47%) 62 (41%) 15 (42%) 
 Female 32 (53%) 88 (59%) 21 (58%) 
     
Age <65 7 (12%) 8 (5%) 1 (3%) 
 65-74 24 (40%) 29 (19%) 6 (17%) 
 75-84 19 (32%) 85 (57%) 21 (58%) 
 >85 10 (16%) 28 (19%) 8 (22%) 
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Figure 1 
Scree test plot of component eigenvalues 
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Table 2 
Two-factor structure of BASQID items (n=143) 
 Question Content Component 1 
LS 
Component 2 
FPQ 
Q1 How satisfied are you with your health? .647 .167 
Q2 How satisfied are you with your ability to 
look after yourself? 
.655 .178 
Q3 How satisfied are you with your level of 
energy? 
.664 .272 
Q4 How satisfied are you with your enthusiasm 
for doing things? 
.731 .162 
Q5 How satisfied are you with the way you 
usually spend your day? 
.651 .289 
Q6 How satisfied are you with your level of 
independence? 
.671 .364 
Q7 How satisfied are you with your personal 
relationships? 
.577 .328 
Q8 How satisfied are you with your ability to talk 
to other people? 
.565 .092 
Q9 To what extent are you able to move around 
your local community? 
.257 .685 
Q10 To what extent are you able to do all the 
activities that you want to? 
.328 .688 
Q11 To what extent are you able to things that you 
enjoy? 
.302 .761 
Q12 To what extent do you feel you have the .136 .771 
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choice to do the things that you want to do? 
Q13 To what extent do you feel useful? .103 .682 
Q14 To what extent do you feel happy? .332 .605 
Shaded areas reflect factor loadings>0.4 
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Table 3 
Correlations between the BASQID scales and the WHOQOL-BREF, GDS-15, MMSE 
and participant age 
 Scale 
 BASQID (n) LS (n) FPQ (n) 
WHOQOL- BREF - Physical .32* (41) .23 (44) .36* (41) 
WHOQOL- BREF - Psychological .39* (41) .37* (44) .37* (41) 
WHOQOL- BREF - Social .59** (30) .61** (33) .50** (30) 
WHOQOL- BREF - Environmental .34* (41) .27 (44) .39* (41) 
GDS-15 .58** (47) .50** (50) .54** (47) 
MMSE -.08 (143) -.07 (143) -.09 (143) 
Age -.12 (143) .09 (143) .12 (143) 
* Significance level of p<0.05 
** Significance level of p<0.01 
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Table 4 
BASQID Change scores and effect sizes for Sub-sample A, grouped according to 
Clinician Global Change Ratings 
Clinician Global 
Change Rating 
Scale Mean change in 
scores 
Mean 
Effect Size
Effect Size 
95% Confidence 
Interval 
Worse QoL  BASQID -5.00 -.67 -1.34 to .00 
(n=3) LS -2.33 -.55 -1.22 to .12 
  FPQ -2.66 -.63 -1.30 to .04 
     
Same QoL  BASQID -.04 .00 -.25 to .25 
(n=23) LS -.17 -.04 -.47 to .39 
  FPQ .13 .03 -.22 to .28 
     
Better QoL  BASQID 3.20 .43 .13 to .73 
(n=10) LS 2.30 .54 .14 to .93 
 FPQ .90 .22 -.07 to .50 
 
 
 
